The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for relacorilant to treat patients with Cushing syndrome (hypercortisolism).

Cushing's syndrome is a debilitating disorder which requires rapid reversal of hypercortisolemia to limit morbidity. The primary treatment for Cushing's syndrome remains surgical although residual ...

Horses change their coat depending on the season — a thick winter coat protects them from the cold, while a shorter coat keeps them cool in summer. But what happens when the coat doesn't change? In ...

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well ...

Xeris Biopharma (XERS), a fast-growing biopharmaceutical company, beat top and bottom-line expectations for Q4 and announced it is expecting ...

Corcept Therapeutics (CORT) announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous ...

such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an increasing awareness that the clinical expression ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Scientists have identified a potential new benefit of a well-known drug: extending lifespan by improving mitophagy, the ...

Supplements to reduce cortisol have been rising in popularity. They claim to lower stress levels. Are they legit?